Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US
- Compatibility tests for closed infusion system with HDP-101 successfully completed
- Shipping of study medication to the US in preparation
- Contract signed with first study center, MD Anderson Cancer Center; initiation of the center planned in the near future
Heidelberg Pharma AG today announced that preparations for the initiation of the Phase I/IIa clinical trial with HDP-101 have progressed and the initiation of the first study site, the MD Anderson Cancer Center, Houston, TX, US, is planned shortly.